

CASE STUDY

Optimising treatment pathways.

Heart Valve disease (hVd) effects around 1 in 2 of people over 65 to some extent.

Those with severe HVD have a five-year survival rate of only 3% without treatment which is worse than many common cancers. With the number of people in the UK with moderate to severe HVD set to grow from the current 1.5 million to 3.3 million by 2056, Edwards Lifesciences wanted to better understand the needs of this large patient group.

Edwards Lifesciences selected Quantis to deliver real insight into the existing HVD situation. Using hospital admission (HES) data Quantis provided insight to better understand the needs of HVD patients.

It investigated the numbers of people having procedures to manage aortic stenosis, in particular; drugs, palliation, open heart surgery and TAVI procedures.

Insight delivered where you need it most.

There is a range of Quantis solutions to meet your specific requirements. From a single analytics report exploring a specific area, to a bespoke dashboard solution with the latest data visualisation capabilities that provides insight whenever you require.

Discover how Quantis can align your value proposition with the needs of the NHS.

For more information email
info@wilmingtonhealthcare.com

Quantis outcomes.

- Identified that treating patients with TAVI reduced the cost of managing AS by £20,000 per patient
- Identified how minimally invasive TAVI procedures resulted in better outcomes for patients, reduced hospital stays, fewer complications and significantly increased life expectancy
- Enabled adoption of a RightCare approach to develop optimal care pathways for HVD patients

Read a detailed overview [here](#)

Platform options.

1. Quantis Dashboards

- Five year data capacity
- Latest data visualisation
- Cloud-based solution

2. Quantis Analytic Reports

- Focused
- Bespoke
- Fast

3. Quantis iPad App

- Offline
- Bespoke data
- Easy to use

